Cytek Biosciences (CTKB) Competitors

Cytek Biosciences logo
$5.34 -0.27 (-4.81%)
Closing price 02/7/2025 04:00 PM Eastern
Extended Trading
$5.34 0.00 (0.00%)
As of 02/7/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CTKB vs. TXG, TRNS, LAB, SENS, EYPT, ALNT, QTRX, AEHR, QSI, and NAUT

Should you be buying Cytek Biosciences stock or one of its competitors? The main competitors of Cytek Biosciences include 10x Genomics (TXG), Transcat (TRNS), Standard BioTools (LAB), Senseonics (SENS), EyePoint Pharmaceuticals (EYPT), Allient (ALNT), Quanterix (QTRX), Aehr Test Systems (AEHR), Quantum-Si (QSI), and Nautilus Biotechnology (NAUT). These companies are all part of the "measuring and control equipment" industry.

Cytek Biosciences vs.

Cytek Biosciences (NASDAQ:CTKB) and 10x Genomics (NASDAQ:TXG) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Cytek Biosciences presently has a consensus price target of $6.50, indicating a potential upside of 21.72%. 10x Genomics has a consensus price target of $23.86, indicating a potential upside of 67.42%. Given 10x Genomics' stronger consensus rating and higher possible upside, analysts clearly believe 10x Genomics is more favorable than Cytek Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytek Biosciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
10x Genomics
1 Sell rating(s)
7 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.53

Cytek Biosciences has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500.

Cytek Biosciences has higher earnings, but lower revenue than 10x Genomics. Cytek Biosciences is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cytek Biosciences$193.01M3.56-$12.15M-$0.08-66.74
10x Genomics$618.73M2.79-$255.10M-$1.53-9.31

10x Genomics received 35 more outperform votes than Cytek Biosciences when rated by MarketBeat users. Likewise, 51.89% of users gave 10x Genomics an outperform vote while only 44.44% of users gave Cytek Biosciences an outperform vote.

CompanyUnderperformOutperform
Cytek BiosciencesOutperform Votes
20
44.44%
Underperform Votes
25
55.56%
10x GenomicsOutperform Votes
55
51.89%
Underperform Votes
51
48.11%

Cytek Biosciences has a net margin of -5.05% compared to 10x Genomics' net margin of -28.93%. Cytek Biosciences' return on equity of -2.58% beat 10x Genomics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cytek Biosciences-5.05% -2.58% -2.05%
10x Genomics -28.93%-25.07%-19.41%

In the previous week, 10x Genomics had 6 more articles in the media than Cytek Biosciences. MarketBeat recorded 10 mentions for 10x Genomics and 4 mentions for Cytek Biosciences. 10x Genomics' average media sentiment score of 0.19 beat Cytek Biosciences' score of 0.17 indicating that 10x Genomics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cytek Biosciences
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
10x Genomics
1 Very Positive mention(s)
5 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 9.6% of Cytek Biosciences shares are owned by company insiders. Comparatively, 10.0% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

10x Genomics beats Cytek Biosciences on 13 of the 19 factors compared between the two stocks.

Get Cytek Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CTKB vs. The Competition

MetricCytek BiosciencesAnalytical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$722.63M$5.70B$5.76B$9.10B
Dividend YieldN/A0.42%5.30%4.00%
P/E Ratio-66.7422.8388.3619.38
Price / Sales3.564.101,023.4981.37
Price / Cash222.4140.4546.1438.79
Price / Book1.842.305.134.75
Net Income-$12.15M-$10.70M$114.46M$222.93M
7 Day Performance3.69%-2.33%-0.48%0.14%
1 Month Performance-21.82%-1.59%0.10%-0.13%
1 Year Performance-34.72%-21.57%23.94%21.24%

Cytek Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CTKB
Cytek Biosciences
1.0182 of 5 stars
$5.34
-4.8%
$6.50
+21.7%
-32.1%$722.63M$193.01M-66.74500
TXG
10x Genomics
4.0464 of 5 stars
$14.45
-3.7%
$23.86
+65.1%
-69.1%$1.75B$618.73M-9.441,240
TRNS
Transcat
3.6155 of 5 stars
$77.22
+0.3%
$111.50
+44.4%
-29.3%$710.42M$259.48M41.741,104Analyst Downgrade
LAB
Standard BioTools
2.5253 of 5 stars
$1.47
-5.2%
$2.88
+95.6%
-41.8%$547.22M$106.34M-2.07620
SENS
Senseonics
2.6112 of 5 stars
$0.90
-6.8%
$2.00
+123.4%
+96.2%$532.88M$22.39M-6.8990News Coverage
EYPT
EyePoint Pharmaceuticals
1.578 of 5 stars
$7.17
-6.3%
$26.63
+271.3%
-77.9%$489.35M$46.02M-3.59120Analyst Forecast
News Coverage
Gap Up
ALNT
Allient
4.1734 of 5 stars
$24.42
-3.1%
$29.33
+20.1%
-13.6%$411.23M$578.63M27.752,287Positive News
Gap Down
QTRX
Quanterix
2.6773 of 5 stars
$8.83
-3.9%
$23.25
+163.3%
-65.8%$340.13M$122.37M-8.33460
AEHR
Aehr Test Systems
3.2943 of 5 stars
$10.77
-4.9%
$25.00
+132.1%
-29.8%$319.98M$66.22M14.3690
QSI
Quantum-Si
2.7341 of 5 stars
$1.82
-8.1%
$3.25
+78.6%
+42.7%$259.73M$1.08M-2.84150Analyst Forecast
Gap Up
NAUT
Nautilus Biotechnology
2.1832 of 5 stars
$1.71
flat
$3.58
+109.6%
-40.0%$214.71MN/A-3.05130

Related Companies and Tools


This page (NASDAQ:CTKB) was last updated on 2/8/2025 by MarketBeat.com Staff
From Our Partners